Breast Cancer Survivors Who Were Treated With Hormone Therapy Have Higher Risk Of Diabetes,

reports that research indicated “breast cancer survivors who were treated with either tamoxifen or an aromatase inhibitor (AI) for hormone receptor-positive breast cancer were significantly more likely to develop diabetes during a median follow-up of 5.9 years compared with women who did not have hormonal therapy.” In the “study of 2,246 female breast cancer patients with no history of diabetes before their diagnosis or in the first year thereafter,” researchers “found that hormone therapy increased the risk of diabetes by almost 2.5 times on multivariable-adjusted analysis compared with those who did not have hormone therapy.” The findings were published online in the Journal of Clinical Oncology. https://www.medpagetoday.com/hematologyoncology/breastcancer/72737